Back to top
more

X4 Pharmaceuticals (XFOR)

(Delayed Data from NSDQ)

$1.17 USD

1.17
11,090,820

+0.04 (3.10%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.18 +0.02 (1.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XFOR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

X4 Pharmaceuticals, Inc. [XFOR]

Reports for Purchase

Showing records 1 - 20 ( 91 total )

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/22/2024

Company Report

Pages: 6

Eyes on Mavorixafor April 30 PDUFA in WHIM Syndrome; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/11/2023

Daily Note

Pages: 4

Promising Additional Phase 2 Data in CND; Awaiting Next Clinical Update in 1H24; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/10/2023

Company Report

Pages: 7

PDUFA Date Set; Initiation of Phase 3 Study in CND in 1H24; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/11/2023

Company Report

Pages: 8

NDA Filing in WHIM Imminent; Positive Phase 2 Update Supports MavorixaforÂ’s Potential in CND; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/05/2023

Company Report

Pages: 6

NDA Filing in WHIM Imminent; KOL Event on May 16; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

03/22/2023

Company Report

Pages: 6

NDA Filing in WHIM and Long-term Chronic Neutropenia Data in 2H23; PT Lowered To $3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/30/2022

Company Report

Pages: 7

Successful 4WHIM Paves Way For 1H24 Launch; Raise PT to $5; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/04/2022

Company Report

Pages: 7

All Eyes on 4WHIM Top-Line in 4Q22; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/28/2022

Daily Note

Pages: 5

Mavorixafor Scores in Chronic Neutropenia; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/05/2022

Company Report

Pages: 9

Key Readouts Remain on Track; Lower PT to $3.50 on Dilution; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/22/2022

Daily Note

Pages: 3

Strategic Operational Restructuring to Extend Cash Runway into 3Q23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

06/09/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/13/2022

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/13/2022

Company Report

Pages: 7

Potential Mavorixafor NDA for WHIM in 2H23; Lower PT to $8.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/13/2022

Company Report

Pages: 6

1Q2022 Update - Big Year for Mavorixafor With 3 Clinical Data Updates

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/12/2022

Industry Report

Pages: 3

AACR Presentation Takesways

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/18/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: X4 Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/18/2022

Company Report

Pages: 7

WHIM Phase 3 Top Line in 4Q22; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party